TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16824996

Group type: EXPERIMENTAL
Intervention: Doppler tissue imaging (DTI)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Pulsed wave Doppler
Number of subjects: 278

Group type: COMPARATOR
Intervention: Color M-mode (CMM)
Number of subjects: 278
Study: 14625334

Group type: EXPERIMENTAL
Intervention: High-energy ESWT
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Low-energy ESWT
Number of subjects: 144

Group type: COMPARATOR
Intervention: Sham treatment (placebo)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: High-energy ESWT and Low-energy ESWT
Number of subjects: 144
Study: 11092294

Group type: EXPERIMENTAL
Intervention: 1,800 IU vitamin E therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9062860

Group type: EXPERIMENTAL
Intervention: Triclosan at 0.125%-1% in absolute alcohol (experiment 1)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Triclosan at 0.5% in various solvents (experiment 2)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Triclosan at 0.5% in various solvents (experiment 3)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Saline solution (negative control in experiments 2 and 3)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Absolute alcohol (positive control in experiments 2 and 3)
Number of subjects: 33
Study: 8072836

Group type: EXPERIMENTAL
Intervention: High dose RSV immunoglobulin (RSVIG)
Number of subjects: 249
Study: 2553511

Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide
Number of subjects: 64

Group type: COMPARATOR
Intervention: Bulk laxative (plantago rind and sorbitol)
Number of subjects: 64
Study: 360231

Group type: EXPERIMENTAL
Intervention: Mianserine (ORG GB 94)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study: 31626301

Group type: EXPERIMENTAL
Intervention: Operant learning group
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Energy conservation group
Number of subjects: 69
Study: 30317839

Group type: EXPERIMENTAL
Intervention: Cognitive demanding task (Stroop) for 60 min
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control condition (equivalent time without cognitive task)
Number of subjects: 13
Study: 28613956

Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg/day
Number of subjects: 392
Study: 26931362

Group type: EXPERIMENTAL
Intervention: Proactive outreach intervention (tailored mailings and telephone calls) with free cessation treatment (nicotine replacement therapy and intensive telephone counselling)
Number of subjects: 2406

Group type: EXPERIMENTAL
Intervention: Proactive outreach intervention
Number of subjects: 2406

Group type: COMPARATOR
Intervention: Usual care (access to a primary care physician, insurance coverage of FDA-approved smoking cessation medications, and the state's telephone quitline)
Number of subjects: 2406

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2406
Study: 23581280

Group type: EXPERIMENTAL
Intervention: AMICUS
Number of subjects: 30

Group type: COMPARATOR
Intervention: COBE Spectra
Number of subjects: 30
Study: 21802078

Group type: COMPARATOR
Intervention: Standard-definition white-light (SD-WL) colonoscopy
Number of subjects: 630

Group type: COMPARATOR
Intervention: High-definition white-light (HD-WL) colonoscopy
Number of subjects: 630

Group type: COMPARATOR
Intervention: Narrow-band imaging (NBI) colonoscopy
Number of subjects: 630
Study: 19635962

Group type: EXPERIMENTAL
Intervention: Ceftazidime 2 g three times a day
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Ceftazidime 6 g per day continuously
Number of subjects: 49

Group type: COMPARATOR
Intervention: Ceftazidime (general)
Number of subjects: 49
Study: 16430548

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 60
Study: 15307988

Group type: EXPERIMENTAL
Intervention: Retinoscopy of combined positive cylinders with negative cylinders (experiment group)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Conventional retinoscopy (control group)
Number of subjects: 189
Study: 11380911

Group type: EXPERIMENTAL
Intervention: Additional IVIG treatment (1 g/kg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Steroid pulse therapy
Number of subjects: 35
Study: 8946097

Group type: EXPERIMENTAL
Intervention: Xylitol pellet gum
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Sorbitol pellet gum
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Xylitol stick gum
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Sorbitol stick gum
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Xylitol/sorbitol mixtures in pellet form
Number of subjects: 510

Group type: COMPARATOR
Intervention: No gum
Number of subjects: 510
Study: 1827003

Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg twice daily
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 7043448

Group type: EXPERIMENTAL
Intervention: Clomiphene
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combined clomiphene-parlodel treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Parlodel
Number of subjects: 22
Study: 30381412

Group type: EXPERIMENTAL
Intervention: Patiromer 8.4 g once daily without/with food for 4 weeks
Number of subjects: 112
Study: 28984632

Group type: EXPERIMENTAL
Intervention: Allopurinol 600 mg orally administered on the day before PCI and on the day of PCI
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo (no allopurinol pretreatment)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 26523821

Group type: EXPERIMENTAL
Intervention: Pediatrician-only SBIRT implementation
Number of subjects: 1871

Group type: EXPERIMENTAL
Intervention: Embedded BHCP SBIRT implementation
Number of subjects: 1871
Study: 23640923

Group type: COMPARATOR
Intervention: Recombinant lipocalin-2 (rLcn2) injected into chow-fed mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High fat (HF) meals given to NW and OB women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lcn2 treatment in adipocytes
Number of subjects: 0
Study: 21209304

Group type: EXPERIMENTAL
Intervention: Traditional treatment plus religious and spiritual assessment
Number of subjects: 78

Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 78
Study: 20183688

Group type: EXPERIMENTAL
Intervention: Computer-aided psychotherapy (CP)
Number of subjects: 23
Study: 17225971

Group type: EXPERIMENTAL
Intervention: VR-Lab sessions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: P-Lab sessions
Number of subjects: 12

Group type: COMPARATOR
Intervention: VR-Lab
Number of subjects: 12
Study: 15569835

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg and losartan 100 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Simvastatin 20 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Losartan 100 mg
Number of subjects: 47
Study: 11224005

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Fasting glucose, fasting insulin, insulin 120 min after glucose ingestion
Number of subjects: 113
Study: 9846679

Group type: EXPERIMENTAL
Intervention: GnRH-agonist down regulation for 15-24 days (Group A)
Number of subjects: 86

Group type: COMPARATOR
Intervention: GnRH-agonist down regulation for 25-40 days (Group B)
Number of subjects: 86
Study: 7855098

Group type: EXPERIMENTAL
Intervention: Tea consumption (8 g of instant tea) during supplementation periods in Study A
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tea consumption (8 g of instant tea) during supplementation periods in Study B
Number of subjects: 18

Group type: COMPARATOR
Intervention: No tea dietary treatments in Study A
Number of subjects: 18

Group type: COMPARATOR
Intervention: No tea dietary treatments in Study B
Number of subjects: 18
Study: 2239725

Group type: EXPERIMENTAL
Intervention: Full-dose labetalol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Half-dose labetalol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Digoxin with half-dose labetalol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Digoxin with full-dose labetalol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 417581

Group type: EXPERIMENTAL
Intervention: 4.5 g of iopronic acid
Number of subjects: 180

Group type: COMPARATOR
Intervention: 3.0 g of iopanoic acid
Number of subjects: 180
Study: 31152584

Group type: EXPERIMENTAL
Intervention: Aerated conditions with high nutrient levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stagnant conditions with high nutrient levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerated conditions with low nutrient levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stagnant conditions with low nutrient levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerated conditions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stagnant conditions
Number of subjects: 0
Study: 28667579

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) 3000 mg plus wheat germ oil (WGO) 300 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 26126970

Group type: COMPARATOR
Intervention: Weekly paclitaxel (WP) for 12 treatments
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Eribulin (E) every 3 weeks for 4 cycles followed by doxorubicin and cyclophosphamide (AC) every 3 weeks for 4 cycles
Number of subjects: 50
Study: 23444963

Group type: EXPERIMENTAL
Intervention: High kimchi intake (210 g/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low kimchi intake (15 g/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (low and high kimchi intake)
Number of subjects: 100
Study: 21138357

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) combined with bovine-derived xenograft (BDX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Platelet-poor plasma (PPP) combined with bovine-derived xenograft (BDX)
Number of subjects: 20
Study: 19173710

Group type: EXPERIMENTAL
Intervention: Alanine-glutamine infusion at a rate of 0.025 g/(kg body weight x hour) for 10 hours
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion for 10 hours
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alanine-glutamine infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study: 17300878

Group type: EXPERIMENTAL
Intervention: Nicotine patch 21 mg/day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nicotine patch 42 mg/day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nicotine patch 63 mg/day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 14996516

Group type: EXPERIMENTAL
Intervention: Epinastine hydrochloride 0.05% ophthalmic solution
Number of subjects: 67

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 67
Study: 11817197

Group type: EXPERIMENTAL
Intervention: Counseling interventions (two types)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 0
Study: 9006598

Group type: EXPERIMENTAL
Intervention: Nurse-initiated daily phone calls program
Number of subjects: 0
Study: 8252685

Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Diatrizoate
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 25

Group type: COMPARATOR
Intervention: Contrast agents (general)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 25
Study: 3520469

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate potassium (Augmentin)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 29520826

Group type: EXPERIMENTAL
Intervention: Triclosan-containing toothpaste (triclosan/copolymer/fluoride toothpaste), used three times/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (fluoride toothpaste), used three times/day
Number of subjects: 22
Study: 27400316

Group type: COMPARATOR
Intervention: BNP reduction tertile 1 (<27pg/mL)
Number of subjects: 245

Group type: COMPARATOR
Intervention: BNP reduction tertile 2 (27-334pg/mL)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: BNP reduction tertile 3 (>334pg/mL)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Whole cohort BNP reduction
Number of subjects: 245
Study: 24756139

Group type: EXPERIMENTAL
Intervention: Early variations of parotid gland density (rΔρ)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Early variations of parotid gland volume (rΔvol)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Early rΔρ and rΔvol
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Median early density rate changes
Number of subjects: 46
Study: 22065088

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAAs) and associated catabolites
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Independent cohort validation
Number of subjects: 500
Study: 19618992

Group type: EXPERIMENTAL
Intervention: Simvastatin and L-carnitine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Simvastatin monotherapy
Number of subjects: 75
Study: 17502531

Group type: EXPERIMENTAL
Intervention: Hypothetical trial scenarios with various factors (adverse effects, trial durations, sponsors, financial incentives, conflicts of interest)
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Perceived probability of harm
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Perceived health benefit
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Perceived quality of care
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Disclosure of investigator patent ownership
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Monetary incentives
Number of subjects: 783
Study: 15204348

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate pMDI 200 microg b.i.d.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Budesonide pMDI 200 microg b.i.d.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11576621

Group type: EXPERIMENTAL
Intervention: Cushing's disease
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Adrenal tumors
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Healthy volunteers after ACTH stimulation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 44
Study: 9700881

Group type: EXPERIMENTAL
Intervention: Urogenital chlamydiosis
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Furunculosis
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Urogenital herpes
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 8053613

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (800 mg/d)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 2498584

Group type: EXPERIMENTAL
Intervention: Service A (one medical school)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Service B (another medical school)
Number of subjects: 119
Study: 6135430

Group type: EXPERIMENTAL
Intervention: GP 55 129 (4 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31440873

Group type: EXPERIMENTAL
Intervention: Simulated game 'Lucky Lolly Slots' played for at least 5 min each week for 24 weeks
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Simulated game 'Lucky Lolly Slots'
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Participants trying to reduce expenditure
Number of subjects: 736
Study: 31094144

Group type: EXPERIMENTAL
Intervention: PMMA incorporating chlorhexidine (CHX)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control discs (without CHX)
Number of subjects: 32
Study: 27936344

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) administration of HZ/su vaccine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intramuscular (IM) administration of HZ/su vaccine
Number of subjects: 60
Study: 25678009

Group type: EXPERIMENTAL
Intervention: Intravenous oseltamivir 100 or 200 mg every 12 h for 5 days
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Intravenous oseltamivir
Number of subjects: 118
Study: 24378599

Group type: EXPERIMENTAL
Intervention: Infliximab retreatment
Number of subjects: 29
Study: 22012543

Group type: EXPERIMENTAL
Intervention: Magnesium Group (10% magnesium sulphate 2 mL)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Saline Group (normal saline 2 mL)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Magnesium Group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 66
Study: 20889389

Group type: EXPERIMENTAL
Intervention: Study Care (SC): reassurance and avoidance of passive treatments, acetaminophen, 4 weeks of lumbar chiropractic spinal manipulative therapy (CSMT), and return to work within 8 weeks
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual Care (UC): family physician-directed usual care
Number of subjects: 92
Study: 18065731

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: True acupuncture after crossover from sham
Number of subjects: 72
Study: 15894536

Group type: EXPERIMENTAL
Intervention: External swing assist (ESA) device applying forces up to 4% body weight
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal running
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External swing assist (ESA) device
Number of subjects: 0
Study: 12478337

Group type: EXPERIMENTAL
Intervention: JET therapy (carboplatin 300 mg/m² on day 1 and etoposide 60 mg/m² on days 1 to 5, repeated every 6 weeks)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: JET therapy
Number of subjects: 28
Study: 9650682

Group type: EXPERIMENTAL
Intervention: Dexamethasone palmitate (liposteroid) therapy (0.25 mg/kg, administered intravenously seven times over 3 months, total dosage = 1.75 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: ACTH therapy (0.025 mg/kg/day, administered intramuscularly for 6 weeks, total dosage = 0.625 mg/kg)
Number of subjects: 10
Study: 8135428

Group type: EXPERIMENTAL
Intervention: 50‐mL bolus of D50W followed by a normal saline infusion at 125 mL/hr for three hours
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 50‐mL bolus of D50W followed by an infusion of 2/3:1/3 dextrose:saline solution at 125 mL/hr for three hours
Number of subjects: 36

Group type: COMPARATOR
Intervention: 50‐mL normal saline bolus followed by a normal saline infusion at 125 mL/hr for three hours
Number of subjects: 36
Study: 2812853

Group type: EXPERIMENTAL
Intervention: Topical anaesthetic cream, EMLA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 884925

Group type: EXPERIMENTAL
Intervention: Ethanol alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Whiskey
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ethanol with n-propyl, n-butyl, and isoamyl alcohols
Number of subjects: 6

Group type: COMPARATOR
Intervention: Ethanol alone, Whiskey, Ethanol with n-propyl, n-butyl, and isoamyl alcohols
Number of subjects: 6
Study: 31015261

Group type: EXPERIMENTAL
Intervention: IL‐1 trap (study A)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: IL‐1 receptor antagonist (study B)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (study A)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (study B)
Number of subjects: 46
Study: 27514629

Group type: EXPERIMENTAL
Intervention: Supervised yoga training with treatment as usual (TAU)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Supervised physical exercise training with treatment as usual (TAU)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Supervised yoga training (YT) or supervised physical exercise training (PE)
Number of subjects: 286
Study: 25620313

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 566

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 566
Study: 23490327

Group type: EXPERIMENTAL
Intervention: 16 Gy plus pro re nata (PRN) ranibizumab
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: 24 Gy plus PRN ranibizumab
Number of subjects: 230

Group type: COMPARATOR
Intervention: Sham 16 Gy plus PRN ranibizumab
Number of subjects: 230

Group type: COMPARATOR
Intervention: Sham 24 Gy plus PRN ranibizumab
Number of subjects: 230
Study: 21652615

Group type: EXPERIMENTAL
Intervention: sILMA™ with sILMA™ tracheal tube
Number of subjects: 80

Group type: COMPARATOR
Intervention: i-gel™ with Magill PVC tube
Number of subjects: 80
Study: 19698859

Group type: EXPERIMENTAL
Intervention: Hetastarch
Number of subjects: 156

Group type: COMPARATOR
Intervention: Albumin
Number of subjects: 156
Study: 17547798

Group type: EXPERIMENTAL
Intervention: Dixson 0.75 kcal/ml (TPF-DM)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Nutrition MF 0.75 kcal/ml (standard formula)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both enteral nutrition formulas
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both enteral nutrients
Number of subjects: 76
Study: 15337732

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d for 1 month followed by 80 mg/d thereafter
Number of subjects: 4497

Group type: COMPARATOR
Intervention: Placebo for 4 months followed by 20 mg/d of simvastatin
Number of subjects: 4497

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/d
Number of subjects: 4497

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d
Number of subjects: 4497

Group type: EXPERIMENTAL
Intervention: Simvastatin only group (40 mg/80 mg)
Number of subjects: 4497

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4497
Study: 11351146

Group type: EXPERIMENTAL
Intervention: Constipation-predominant IBS
Number of subjects: 22

Group type: COMPARATOR
Intervention: Diarrhea-predominant IBS
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control subjects (normal bowel habits)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: All study groups
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 5-hydroxyindoleacetic acid concentrations
Number of subjects: 22
Study: 9539277

Group type: EXPERIMENTAL
Intervention: Oxisensor FS10 (660 + 890 nm)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Oxisensor FS14 (735 + 890 nm)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Pulse oximetry
Number of subjects: 112